Monthly Archives: July 2008

What is Your Digital Literacy?

I’ve been writing a lot about the role of digital in pharmaceutical communications.  If  you don’t like that, you aren’t going to enjoy this posting. Sunday’s New York Times carried a highly interesting and large article called "Literacy Debate:  Online, … Continue reading

Posted in Uncategorized | 4 Comments

Eisai Gets Thumbs Down Action Letter

Another action from the FDA today that gives a thumbs down to an investigational drug.  Today Eisai announced that it had received a non-approvable letter for the investigational compound fospropofol disodium injection which has been in review at the FDA … Continue reading

Posted in Uncategorized | 5 Comments

A Not Approvable Letter That Outlines What is Necessary for Approval

This morning, Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced receipt of a not approvable letter from the FDA for iloperidone, an investigational atypical antipsychotic that was reviewed for the treatment of schizophrenia.  It is noteworthy on a few fronts. First, it … Continue reading

Posted in Approvable Letters | 1 Comment

GSK Gets on Board with The YouTube Revolution –

In place of the Weekly Roundup this week, I am writing a regular post because of a new development I just saw on Twitter from my friend Brian Reid.  So ok folks, first J&J got on board by creating their … Continue reading

Posted in New and Social Media | 3 Comments

Genentech Forms Special Committee of Independent Directors to Review Roche Proposal

I’ve decided to add a new category for Business/Industry News.  In these cases, the posting will be a re-print of press releases affecting the industry that I find of high interest.  This one is from Genentech on the Roche offer. … Continue reading

Posted in Business/Industry News | Comments Off on Genentech Forms Special Committee of Independent Directors to Review Roche Proposal